Ascelia Pharma AB (publ)

OM:ACE Stock Report

Market Cap: SEK 400.6m

Ascelia Pharma Valuation

Is ACE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of ACE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: ACE (SEK3.08) is trading below our estimate of future cash flow value (SEK30.59)

Significantly Below Future Cash Flow Value: ACE is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACE?

Key metric: As ACE is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ACE. This is calculated by dividing ACE's market cap by their current book value.
What is ACE's PB Ratio?
PB Ratio5x
BookSEK 82.92m
Market CapSEK 400.61m

Price to Book Ratio vs Peers

How does ACE's PB Ratio compare to its peers?

The above table shows the PB ratio for ACE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.3x
IMMU Mendus
0.7x42.05%SEK 380.4m
IVACC Intervacc
1.7x3.76%SEK 443.1m
SPRINT Sprint Bioscience
4.4xn/aSEK 469.5m
CANTA Cantargia
2.3x-54.75%SEK 533.5m
ACE Ascelia Pharma
5x104.91%SEK 411.3m

Price-To-Book vs Peers: ACE is expensive based on its Price-To-Book Ratio (5x) compared to the peer average (2.3x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does ACE's PB Ratio compare vs other companies in the SE Biotechs Industry?

11 CompaniesPrice / BookEstimated GrowthMarket Cap
XBRANE Xbrane Biopharma
0.4xn/aUS$22.65m
SUBGEN Subgen AI
0.1xn/aUS$4.90m
APTA Aptahem
0.2xn/aUS$1.33m
CYXO Cyxone
0.2xn/aUS$615.55k
ACE 5.0xIndustry Avg. 3.0xNo. of Companies11PB0246810+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ACE is expensive based on its Price-To-Book Ratio (5x) compared to the Swedish Biotechs industry average (3x).

Price to Book Ratio vs Fair Ratio

What is ACE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ACE's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ACE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 3.08
SEK 5.60
+81.82%
36.20%SEK 8.50SEK 3.70n/a4
Jun ’27SEK 3.00
SEK 5.60
+86.67%
36.20%SEK 8.50SEK 3.70n/a4
May ’27SEK 3.00
SEK 6.32
+110.56%
29.48%SEK 8.50SEK 3.95n/a3
Apr ’27SEK 2.81
SEK 6.32
+124.79%
29.48%SEK 8.50SEK 3.95n/a3
Mar ’27SEK 3.14
SEK 6.32
+101.49%
29.48%SEK 8.50SEK 3.95n/a3
Feb ’27SEK 2.65
SEK 6.92
+161.50%
28.36%SEK 9.50SEK 4.75n/a3
Jan ’27SEK 3.22
SEK 6.92
+115.14%
28.36%SEK 9.50SEK 4.75n/a3
Dec ’26SEK 2.64
SEK 6.92
+162.00%
28.36%SEK 9.50SEK 4.75n/a3
Nov ’26SEK 3.21
SEK 7.42
+131.41%
35.50%SEK 11.00SEK 4.75n/a3
Oct ’26SEK 3.41
SEK 7.42
+117.82%
35.50%SEK 11.00SEK 4.75n/a3
Sep ’26SEK 4.99
SEK 7.42
+48.78%
35.50%SEK 11.00SEK 4.75n/a3
Aug ’26SEK 4.70
SEK 7.12
+51.58%
41.47%SEK 11.00SEK 3.85n/a3
Jul ’26SEK 4.33
SEK 7.12
+64.36%
41.47%SEK 11.00SEK 3.85n/a3
Jun ’26SEK 4.13
SEK 7.12
+72.32%
41.47%SEK 11.00SEK 3.85SEK 3.003
May ’26SEK 3.26
SEK 6.71
+105.90%
32.55%SEK 10.00SEK 3.85SEK 3.004
Apr ’26SEK 2.79
SEK 7.68
+175.39%
21.32%SEK 10.00SEK 6.50SEK 2.813
Mar ’26SEK 3.48
SEK 7.68
+120.79%
21.32%SEK 10.00SEK 6.50SEK 3.143
Feb ’26SEK 2.92
SEK 8.25
+183.02%
21.21%SEK 10.00SEK 6.50SEK 2.652
Jan ’26SEK 2.92
SEK 8.25
+182.53%
21.21%SEK 10.00SEK 6.50SEK 3.222
Dec ’25SEK 2.90
SEK 8.25
+184.48%
21.21%SEK 10.00SEK 6.50SEK 2.642
Nov ’25SEK 2.18
SEK 9.00
+313.79%
33.33%SEK 12.00SEK 6.00SEK 3.212
Oct ’25SEK 2.30
SEK 9.00
+292.16%
33.33%SEK 12.00SEK 6.00SEK 3.412
Sep ’25SEK 2.20
SEK 14.75
+570.45%
18.64%SEK 17.50SEK 12.00SEK 4.992
Aug ’25SEK 4.37
SEK 17.25
+295.19%
1.45%SEK 17.50SEK 17.00SEK 4.702
Jul ’25SEK 8.40
SEK 17.25
+105.36%
1.45%SEK 17.50SEK 17.00SEK 4.332
Jun ’25SEK 10.52
SEK 17.25
+63.97%
1.45%SEK 17.50SEK 17.00SEK 4.132
SEK 5.6
Fair Value
45.0% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/26 21:36
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ascelia Pharma AB (publ) is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier Sponsored
Lars HevrengDanske Bank
Maria Karlsson OsipovaDNB Carnegie Commissioned Research